Home › Encyclopedia › CJC-1295: Research Status, Identity, and Trial Data
Research / Unapproved

CJC-1295: Research Status, Identity, and Trial Data

Molecular formulaC165H269N47O46
Molecular weight3647.2 g/mol
Registered trials1
PubChem CID91971820

What CJC-1295 Is

CJC-1295 is a synthetic peptide compound identified in chemical databases by PubChem CID 91971820, with a molecular formula of C165H269N47O46. It has no FDA-approved label, meaning there is no agency-reviewed indication, dosing, or safety profile for human use. CJC-1295 remains classified as an unapproved research compound, and any claims about its effects fall outside current regulatory review.

Clinical Trial Footprint

One registered clinical trial involving CJC-1295 appears in the available data. That trial, NCT00267527, was a Phase 2 study evaluating CJC-1295 in HIV patients with visceral obesity. The trial's status is listed as terminated, and this single-record footprint represents a limited and incomplete research history rather than an established evidence base.

FAQ

Is CJC-1295 approved by the FDA?
No. CJC-1295 has no FDA-approved label, meaning there is no agency-reviewed indication, dosage, or confirmed safety profile. It is classified as an unapproved research compound.
What clinical trials have studied CJC-1295?
The available data show one registered trial, NCT00267527, a Phase 2 study of CJC-1295 in HIV patients with visceral obesity. That trial was terminated, so it does not provide completed efficacy or safety conclusions.
What is CJC-1295 chemically?
CJC-1295 is a synthetic peptide with the molecular formula C165H269N47O46 and a PubChem CID of 91971820. This identifies its chemical structure but does not establish any approved medical use.
Are there known side effects of CJC-1295?
No adverse event report data were available for this compound, so a side effect profile cannot be summarized from the current dataset.
Can CJC-1295 be used for research purposes?
It is categorized as unapproved and investigational, with its clinical trial history limited to a single terminated Phase 2 study. No efficacy or safety conclusions can be drawn from this limited record.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 91971820 ClinicalTrials.gov NCT00267527

Updated 2026-11-07